Your browser doesn't support javascript.
loading
Successful guselkumab treatment of a refractory psoriasis patient with Graves' disease: a case report.
Shao, Xinyi; Huang, Kun; Chen, Aijun; Liu, Chuan; Xiong, Jianxia; Pan, Yun; Chen, Xiaoli; Wang, Ping.
Afiliación
  • Shao X; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Huang K; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Chen A; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Liu C; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Xiong J; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Pan Y; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Chen X; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Wang P; Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
J Int Med Res ; 52(4): 3000605241239856, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38656269
ABSTRACT
Psoriasis is a chronic inflammatory skin disease. It is associated with many autoimmune diseases such as rheumatoid arthritis, Crohn's disease and thyroid diseases. Graves' disease (GD) is a common organ-specific autoimmune disease characterized by diffuse goitre and thyrotoxicosis. Management of psoriasis patients with GD is challenging. This current report presents the case of a 34-year-old female patient with refractory psoriasis with GD who was hospitalized for drug eruption and then experienced new-onset erythema and scaling following treatment with adalimumab and secukinumab. Despite the sequential move to phototherapy, tofacitinib and ustekinumab, the erythema and scaling continued unabated and exacerbated. Finally, switching to guselkumab resulted in the psoriasis lesions significantly improving. These findings suggest that guselkumab might be an effective treatment option for refractory psoriasis combined with GD.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Enfermedad de Graves / Anticuerpos Monoclonales Humanizados Límite: Adult / Female / Humans Idioma: En Revista: J Int Med Res Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Enfermedad de Graves / Anticuerpos Monoclonales Humanizados Límite: Adult / Female / Humans Idioma: En Revista: J Int Med Res Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido